Alliqua BioMedical, Inc. Sustainability Profile
Alliqua BioMedical, Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 2011, the company has established itself as a leader in advanced wound care and regenerative medicine, focusing on innovative solutions that enhance patient outcomes. Alliqua's core offerings include a range of proprietary products designed for wound management, such as hydrogel dressings and bioengineered tissue matrices. These products are distinguished by their unique formulations and effectiveness in promoting healing. With a strong market position, Alliqua BioMedical has achieved significant milestones, including strategic partnerships and product approvals that underscore its commitment to advancing healthcare. The company continues to expand its operational reach, serving healthcare providers across various regions in the US and beyond.
DitchCarbon Score
How does Alliqua BioMedical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alliqua BioMedical, Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alliqua BioMedical, Inc.'s reported carbon emissions
Alliqua BioMedical, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. It is important to note that Alliqua BioMedical, Inc. is a merged entity, and any potential emissions data or climate initiatives may be cascaded from its corporate family. However, no specific emissions data or climate commitments have been inherited from related organizations. As the company continues to navigate its environmental responsibilities, it remains crucial for Alliqua BioMedical, Inc. to develop and communicate clear climate commitments and reduction strategies in alignment with industry standards.
How Carbon Intensive is Alliqua BioMedical, Inc.'s Industry?
How Carbon Intensive is Alliqua BioMedical, Inc.'s Location?
Alliqua BioMedical, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alliqua BioMedical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
